HSBC Holdings’s Radiopharm Theranostics RADX Stock Holding History

HSBC Holdings’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Buy	62,188 +816	+1%	+$3.63K	﹤0.01%	2596
2026 Q1	$265K	Sell	61,372 -130,252	-68%	-$637K	﹤0.01%	2504
2025 Q4	$1.01M	Buy	+191,624	New	+$1.02M	﹤0.01%	1942

Other funds holding RADX

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

HSBC Holdings's RADX Position: Q2 2026 in Review

HSBC Holdings increased its Radiopharm Theranostics (RADX) stake by 1.3% in Q2 2026, buying an estimated $3.63K and bringing the position to 62,188 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #2596.

HSBC Holdings first reported a position in RADX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.01M in Q4 2025. 6 funds tracked by Wall St. Rank hold RADX as of Q2 2026.

HSBC Holdings held 62,188 shares of Radiopharm Theranostics worth $254K as of Q2 2026.
HSBC Holdings bought 816 Radiopharm Theranostics shares in Q2 2026, an estimated $3.63K.
Radiopharm Theranostics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2596 holding.
HSBC Holdings first reported a position in Radiopharm Theranostics in Q4 2025 and has held it in 3 quarters since.
HSBC Holdings's Radiopharm Theranostics position peaked at $1.01M in Q4 2025.
6 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.